Anti-GCC antibody and CAR thereof for treating digestive system cancer
AssigneesInnovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.
InventorsLei Xiao, Xiaogang Shen, Wensheng Wang, Dongqi Chen, Beibei Jia, Chengfei Pu, Le Tian
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions and methods of treating a subject having digestive tract cancer, the method comprising: administering an effective amount of a composition to the subject, the composition comprising a first population of cells comprising a first CAR binding a first antigen, and a second population of cells comprising a second CAR binding GCC, wherein the first antigen comprises a cell surface molecule of a white blood cell (WBC).
Claims21
An antibody that binds GCC, wherein the antibody comprises a heavy chain variable region (HVR) comprising amino acid sequence SEQ ID NO:
- 31 and a light chain variable region (LVR) comprising amino acid sequence SEQ ID NO:
- 32 or 41.
Dependencies are inferred from the claim text.